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Abstract
Objectives To develop a high-performance, rapid semi-automatedmethod (Sheffield TKVTool) for measuring total kidney volume
(TKV) from magnetic resonance images (MRI) in patients with autosomal dominant polycystic kidney disease (ADPKD).
Methods TKV was initially measured in 61 patients with ADPKD using the Sheffield TKV Tool and its performance compared
to manual segmentation and other published methods (ellipsoidal, mid-slice, MIROS). It was then validated using an external
dataset of MRI scans from 65 patients with ADPKD.
Results Sixty-one patients (mean age 45 ± 14 years, baseline eGFR 76 ± 32 ml/min/1.73 m2) with ADPKD had a wide range of
TKV (258–3680 ml) measured manually. The Sheffield TKV Tool was highly accurate (mean volume error 0.5 ± 5.3% for right
kidney, − 0.7 ± 5.5% for left kidney), reproducible (intra-operator variability − 0.2 ± 1.3%; inter-operator variability 1.1 ± 2.9%)
and outperformed published methods. It took less than 6 min to execute and performed consistently with high accuracy in an
external MRI dataset of T2-weighted sequences with TKVacquired using three different scanners and measured using a different
segmentation methodology (mean volume error was 3.45 ± 3.96%, n = 65).
Conclusions The Sheffield TKV Tool is operator friendly, requiring minimal user interaction to rapidly, accurately and repro-
ducibly measure TKV in this, the largest reported unselected European patient cohort with ADPKD. It is more accurate than
estimating equations and its accuracy is maintained at larger kidney volumes than previously reported with other semi-automated
methods. It is free to use, can run as an independent executable and will accelerate the application of TKV as a prognostic
biomarker for ADPKD into clinical practice.
Key Points
• This new semi-automated method (Sheffield TKV Tool) to measure total kidney volume (TKV) will facilitate the routine clinical
assessment of patients with ADPKD.
• Measuring TKV manually is time consuming and laborious.
• TKV is a prognostic indicator in ADPKD and the only imaging biomarker approved by the FDA and EMA.
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Abbreviations and acronyms (non-commonly used)
CoV Coefficient of variation
DSC Dice similarity coefficient
HtTKV Height-adjusted total kidney volume
LKV Left kidney volume
LSM Level set method
MIROS Minimal interaction rapid organ segmentation
RKV Right kidney volume
TRUFI True fast imaging with steady-state free precession
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is
the most common inherited kidney disease and fourth leading
cause of end stage renal failure (ESRF) worldwide [1, 2]. It is
characterised by the gradual progressive development and
growth of renal cysts which result in increased total kidney
volume (TKV).
Changes in estimated glomerular filtration rate (eGFR) are
conventionally used to measure loss of kidney function. In
ADPKD, however, eGFR does not change until the later
stages of disease due to compensatory glomerular
hyperfiltration [3] thus limiting its use to late disease [4]. At
earlier stages of disease, increases in TKV are detectable be-
fore decreases in eGFR [5]. A single baseline TKV measure-
ment in combination with age and eGFR (Mayo Imaging
Classification) has been shown to accurately predict future
decline in kidney function [6]. TKV has been approved by
both the US Food and Drug Administration (FDA) and the
EuropeanMedicines Agency (EMA) as a prognostic biomark-
er for disease progression in ADPKD to facilitate the enrich-
ment of patients at a higher risk of rapid progression in future
clinical trials and is currently the only approved imaging bio-
marker [4]. In addition, tolvaptan [7] has been licenced for use
in ADPKD patients in Europe with ‘evidence of rapid disease
progression’. Guidance from the ERA-EDTA recommends
the use of TKV to select higher risk patients for treatment [8].
The current gold standard method for measuring TKV from
MRI involves manual tracing of the kidney boundary on each
MRI slice using dedicated software and summing the product
of area measurements and slice thickness [9]. This is time con-
suming and subject to intra- and inter-operator variability errors.
The alternative method of stereology involves specialised soft-
ware which creates a grid over the kidney [10]. There is a clear
need to develop more rapid and accurate methods for measur-
ing TKV to facilitate its wider adoption into clinical use.
Several semi-automated methods and estimating equations
have been developed to address the challenge of measuring
TKV in ADPKD [11] (summarised in Table S1). Fully auto-
matic methods to estimate TKV have also been reported
[12–14] although they require a good training dataset to in-
clude severely cystic kidneys due to the associated geometric
and anatomical variability. A recent informative review [15]
discusses these different techniques and highlights the need to
translate them into clinical practice to inform disease progres-
sion and treatment decisions. Furthermore, a recent compari-
son of various methods of measuring TKV [16] in ADPKD
concluded that, compared to manual segmentation, existing
methods are insufficiently accurate.
In this paper, we describe the development and validation
of a rapid, high-performance semi-automated method
(Sheffield TKV Tool) for measuring TKV in a representative
group of patients with ADPKD and a wide range of TKV.
Materials and methods
Study population
Sixty-one patients with ADPKD and stage 1–3 chronic kidney
disease (CKD) attending a specialist PKD clinic at Sheffield
Kidney Institute consented to an unenhanced abdominal MRI
for measurement of TKV. Renal function (eGFR [17]) was
measured at baseline (within 1 month of the MRI) and the
most recent follow-up result was recorded (2.00 ± 0.52 years;
0.07–2.72 years). The study was approved by a research ethics
committee (13/YH/026).
MRI acquisition
Kidney MRI scans were coronal true fast imaging with steady-
state free precession (TRUFI) T2-weighted sequences (Siemens
Avanto 1.5-T scanner) with the following parameters: 4 mm
slice thickness, 0 mm slice gap, 2 ms echo time, 3.99 ms rep-
etition time, 60° flip angle, 0.68 × 0.68 mm in plane resolution
and 512 × 512 acquisition matrix. The TRUFI sequence acqui-
sition time was 138 s. This imaging sequence was selected
because its images enabled the clearest delineation of the kid-
ney and associated cysts from neighbouring tissues.
Sheffield TKV Tool development
The Sheffield TKV Tool was implemented using a MATLAB
2016b (MathWorks) framework. The right or left kidney was
segmented individually from coronal MRI slices using image
processing techniques (Fig. 1). Coronal kidney region slices
were selected using mid-sagittal plane (Fig. 1: Step 2). Prior to
segmentation, pre-processing steps were applied to reduce
motion artefact and intra- and inter-slice intensity variations
[18] from the selected coronal slices (Fig. 1: Step 3). Motion
artefact was corrected using affine registration (rotation and
translation) between slices. To correct intra-slice intensity (bi-
as field) variation, entropy minimisation technique was
employed [19]. To correct inter-slice intensity variation, a
technique used by MIROS [18] was employed which
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minimised the mean square error of a threshold-based seg-
mentation (with the number of adjacent voxels greater than
half-slice maximum value) by finding the best-fit linear mul-
tiplier to allow tissue signal homogeneity between slices.
On the cropped region of interest (Fig. 1: Step 4), the user-
defined contour (Fig. 1: Step 5) was propagated using hybrid
level set method (LSM) [20] that utilise edge (gradient) as well
as regional statistics to obtain final segmentation boundary. The
energy function E(ϕ) used in hybrid LSM [20] is given as:
E ϕð Þ ¼ −a ∫
Ω
I−uð ÞH ϕð ÞdΩ þ β ∫
Ω
gj∇H ϕð ÞjdΩ
where ϕ is the level set function. I is the image to be segment-
ed; H(ϕ) is smooth Heaviside function which considers area
around contour; g is image edge (boundary) map where con-
tour should be attracted and is set to be g ¼ 1
1−c ∇ Ij j2 with c
controlling the slope. Ω is the image domain and α and β are
predefined weights to balance two terms. The first term on the
right-hand side of the equation defines that region to be
segmented should have intensity greater than μ which is set
to 50. Parameters α and β are set to 0.01 and 100, respectively.
Evolving contour (level set function) is stopped after 100 iter-
ations to obtain expected kidney region outline (Fig. 1: Step 6).
These parameters were determined experimentally from a ran-
dom dataset of 10. The final contour obtained is not highly
sensitive to the choice of parameters. After segmentation, kid-
ney volume (KV) was calculated by summing the product of
areas of the kidney region and slice thickness. The Sheffield
TKV Tool was applied separately for the right (R) and left (L)
kidneys to enable errors specific to either side to be identified
quickly. The tool was developed and optimised using 10 ran-
dom cases from the patient cohort (training set) and internally
validated on the remaining (51) patient images.
Mayo risk classification
We classified patients in the development cohort into class 1
(typical (bilateral, diffuse)) or class 2 (atypical (unilateral,
Fig. 1 Flow chart of Sheffield TKV Tool. 1. The tool initially loads
DICOM (T2 TRUFI) series. 2. The user selects the approximate sagittal
mid-slice and identifies two points to define the kidney edge which allows
selection of coronal slices that contain the kidney. 3. The selected slices
are pre-processed to remove motion artefact, intra- and inter-slice
intensity variations. Step 3 shows MRI slices before and after pre-
processing respectively. 4. The user previews the cropped image to
check the entire kidney is included within the defined region and 5.
Level set method is manually initialised near the kidney region
boundary (white outline) only on the mid-coronal slice, 6. The final
kidney region outline (white outline) is obtained based on a hybrid
level set method
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segmental, asymmetric cystic disease) based on their kidney
morphology on MRI as defined in the Mayo Imaging classi-
fication [6]. Class 1 patients were further subdivided into cat-
egories 1A–1E, which has been shown to correlate with the
rate of disease progression measured by eGFR change [6].
TKV measurements
To obtain reference TKVmeasurements, the gold standardmeth-
od of manual segmentation was performed using MIMMaestro
on T2 TRUFI coronal MR images of all 61 patients by an expe-
rienced image analyst (A). Analyst Awas blinded to the devel-
opment and TKV measurements of the Sheffield TKV Tool.
Consistent with standard methods of manually measuring TKV
[9, 18], blood vessels in the kidney and hilum (structures includ-
ing ureter, blood vessels and nerves entering each kidney) were
excluded [21]. A second image analyst (B) used the Sheffield
TKVTool (BSheffieldTKVTool1) tomeasure the right (R) and left (L)
kidney volumes (KV) separately and compared its performance
to that of themid-slicemethod [6, 22] andMIROS tool [18] in all
61 patients and used the ellipsoid formula on 51 (typical, class 1)
patients. Images from class 2 patients were excluded from TKV
analysis using the ellipsoid formula because the developers [6]
advise it is not reliable for use in atypical ADPKD since these
patients do not have an ellipsoid kidney shape.
TKV was obtained by summing right and left KV. To apply
the MIROS tool, open-source code was obtained from https://
gitlab.com/Philbrick/rilcontour and re-written in MATLAB. The
MIROS tool was developed for HASTE sequences. TheMIROS
algorithm parameters were tuned on a training set of 10 random
representative (TRUFI image) cases that were used to optimise
the parameters of the MIROS Tool (described in detail in their
methods [18]), particularly parameters alpha (a constant to adjust
the gradient strength) was altered from 1e5 to 1e4 and sigma
(standard deviation of the population) was reduced from 3 to 1.
To assess the inter-operator variability of manual segmen-
tation, analyst B manually (Bmanual1) measured TKV for 40
kidneys from a representative subset of 20 patients (TKV
258–3680 ml) for comparison with TKV already measured
in this dataset by analyst Amanual. Analyst B repeated the man-
ual segmentation on the same dataset after 1 month (Bmanual2)
to assess the intra-operator variability.
To assess the inter-operator variability of the Sheffield TKV
Tool, analystAmeasured TKV for the same dataset of 20 patients
(ASheffieldTKVTool). The intra-operator variability of the Sheffield
TKV Tool was assessed by analyst B on two occasions
(BSheffieldTKVTool1, BSheffieldTKVTool2) separated by 1 month.
Validation of the Sheffield TKV Tool
T2-weighted MRI renal images of 65 ADPKD patients who
participated in the DIPAK-1 study [23] were acquired using
one of three 1.5-T scanners (GE Medical Systems (16),
Siemens (37) and Philips Healthcare (12)). De-identified
DICOM image data from the DIPAK-1 study was transferred
to Groningen Medical Center and converted to the NIFTI file
format by the dcm2nii software. The images had a reconstruct-
ed matrix size of at least 256 × 256 × Z (with Z large enough to
cover the full extent of the kidneys within the imaged volume).
Image voxel sizes weremost commonly on the order of 1.5 mm
in-plane with 4-mm slice thickness and spacing between slices.
The Medical Ethics Committee of University Medical Center
Groningen approved the trial protocol that was conducted in
accordance with the International Conference of Harmonization
Good Clinical Practice Guidelines and in adherence to the
ethics principles that have their origin in the Declaration of
Helsinki. All the patients gave written informed consent.
Kidney boundaries were manually traced using commer-
cially available software AnalyzeDirect 11.0 (AnalyzeDirect
Inc.) and kidney volumes were calculated from the set of
contiguous images by summing the products of the area mea-
surements within the kidney boundaries and slice thickness.
Non-renal parenchyma, e.g. the renal hilum, was excluded
from measurement. Importantly, all measurements were per-
formed by readers blinded for patient number and previous
TKV measurements [9]. Separate KV for the left and right
kidneys was determined using MATLAB software to separate
the measured TKV. The Sheffield TKV Tool was used (ana-
lyst B) to measure TKV on this dataset in a blinded manner
and its performance relative to the reference manual segmen-
tation values was then assessed.
Statistical analyses
Baseline demographics are reported as mean ± standard devi-
ation (SD). Agreement was assessed using Bland-Altman
(BA) analyses to determine the mean difference between
TKV for the various methods. Both actual and percentage
(%) difference in volume were evaluated. For development
of the Sheffield TKV Tool, sample size was calculated for
BA agreement assessment [24] using the level of significance
ρ (type I error), a power value (type II error), expected mean,
SD and maximum acceptable percentage (%) volume differ-
ence between reference and TKV Tool measurements [24].
Based on published literature [12, 18], the expected mean
(bias in BA plot) was 2%, the expected SD (precision in BA
plot) 5% and the maximum allowed difference 15% (greater
than mean + 2SD) [24]. Thus, for ρ of 0.05, a power of 0.80,
the minimum required number of TKV measurement pairs
was 60. Bias (mean) obtained from different methods was
assessed using paired sample t test.
Spatial overlap between segmentation outlines was deter-
mined using the dice similarity coefficient (DSC) [25]. A DSC
value of 1 implies complete overlap while a value of 0 implies
no overlap. Inter- and intra-operator variability were also
assessed by coefficient of variation (CoV) [26].
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Results
Characteristics of the development cohort
Sixty-one ADPKD patients (32 female, 29 male) with a mean
age of 45 ± 14 (20–77) years and eGFR of 76 ± 32 ml/min/
1.73 m2 (33–175 ml/min/1.73 m2) participated in this study.
They represented a wide spectrum of disease with gold stan-
dard TKV ranging (mean ± SD) between 258 and 3680 ml
(1167 ± 798 ml). Their kidneys had variable morphology
(shape, size and heterogeneous cysts) (Fig. 2) and 42 (69%)
patients had liver cysts. Based on the Mayo imaging classifi-
cation [6], 51 patients were categorised as class 1 (typical) and
10 patients as class 2 (atypical disease). Class 1 patients were
further subdivided into five prognostic groups (1A–1E) [6].
Performance of the Sheffield TKV Tool
Table 1 summarises the performance of the Sheffield TKV
Tool, the ellipsoid, mid-slice and MIROS methods compared
to the reference gold standardmanualmethod in all 61 patients
(122 kidneys). The mean TKV of 1153 ± 786 ml (258–
3737 ml), measured by the Sheffield TKV Tool, was close
to manually measured TKV (1167 ± 798 ml; 258–3680 ml),
whereas the ellipsoid (1238 ± 742 ml; 261–3437 ml), mid-
slice (1196 ± 827 ml; 276–4082 ml) and MIROS (1182 ±
821 ml; 261–3780 ml) methods overestimated TKV.
In terms of volume error (Table 1, Fig. 3), the Sheffield
TKV Tool performed more accurately and with greater preci-
sion with a mean TKV difference of − 0.3 ± 3.8% compared to
the ellipsoid (3.1 ± 14.1%), mid-slice (3.8 ± 9.2%) and
MIROS (1.4 ± 5.1%) methods. Paired sample t test however
showed no statistically significant difference (ρ (2-tailed) =
0.008) between bias obtained using the Sheffield TKV Tool
and MIROS method. The Sheffield TKV Tool demonstrated
no particular bias (± ≤ 0.5%) and had a narrower 95% confi-
dence interval. In contrast, the estimating equations were less
reliable with a positive bias (overestimation of TKV) and
more variable results (wider 95% confidence intervals).
Figure S1 shows the high agreement (0.89 ± 0.06 (RKV)
and 0.90 ± 0.04 (LKV) of the DSC for the Sheffield TKVTool
compared to the manual method. There were high inter-
(− 0.5 ± 3.5%, CoV 2.3) and intra- (0.5 ± 2.2%, CoV 1.6)
operator reproducibility for manual TKV measurements.
Inter- (1.1 ± 2.9%, CoV 2.2) and intra- (− 0.2 ± 1.3%, CoV
0.8) operator reproducibility for the Sheffield TKV Tool were
higher than those for manual measurements (Table 2).
Validation of the Sheffield TKV Tool in an external
dataset
The MRI of 65 patients (25 female, 40 male) with ADPKD,
mean age 50 ± 8 (26–61) years and eGFR of 52 ± 13 (33–78)
ml/min/1.73 m2 with a representative spectrum of disease with
Fig. 2 Representative ADPKD kidney MR images used to test Sheffield TKV Tool
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gold standard TKV ranging (mean ± SD) between 400 and
7431 ml (2408 ± 1806 ml) were used. These patients also had
more severe associated polycystic liver disease. Table 3
summarises the performance of the Sheffield TKV Tool com-
pared to the reference gold standard manual method
(AnalyzeDirect) in all 65 patients (130 kidneys). The mean
Table 1 Accuracy and precision
of different semi-automated
methods of measuring or








Right KV Manual (reference) 563 ± 400 – –
Ellipsoid method* 568 ± 394 4.5 ± 19.7 11.0 ± 129.4
Mid-slice method 568 ± 405 1.9 ± 11.1 4.1 ± 72.6
Sheffield TKV Tool 561 ± 392 0.5 ± 5.3 − 2.8 ± 25.3
Left KV Manual (reference) 597 ± 417 – –
Ellipsoid method* 576 ± 378 1.7 ± 17.6 − 21.9 ± 162.9
Mid-slice method 629 ± 452 6.1 ± 12.4 31.8 ± 79.0
Sheffield TKV Tool 592 ± 419 − 0.7 ± 5.5 − 5.1 ± 29.7
TKV Manual (reference) 1167 ± 798 – –
Ellipsoid method* 1238 ± 742 3.1 ± 14.1 − 10.6 ± 223.76
Mid-slice method 1196 ± 827 3.8 ± 9.2 35.9 ± 104.9
MIROS Tool 1182 ± 821 1.4 ± 5.1 21.7 ± 60.8
Sheffield TKV Tool 1153 ± 786 − 0.3 ± 3.8 − 7.9 ± 41.8
Results are shown for all 61 patients (122 kidneys). Negative values indicate underestimation of KV compared to
manual segmentation. Various methods were tested on images of kidneys with manual volumes (analyst A) as
reference. The Sheffield TKV Tool was more accurate and precise compared to the other methods with no bias for
either the left or right kidneys
SD standard deviation, KV kidney volume, TKV total kidney volume
*Results for Ellipsoid method is shown only for class 1 (typical) patients (51 patients)
For MIROS, no separate volumes were obtained for the left and left kidneys, thus results are reported for total
kidney volume (TKV)
Fig. 3 Bland–Altman analysis of
different methods (ellipsoid, mid-
slice, MIROS and Sheffield TKV
Tool) to measure TKV compared
to the reference manual method.
Bland–Altman plots (bold line,
mean; dashed lines, 95%
confidence intervals) comparing
the percentage (%) volume
difference of each method to the
reference manual method to
measure TKV in 61 patients. The
Sheffield TKV Tool demonstrates
higher accuracy and precision
compared to all other methods
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TKVof 2344 ± 1806 ml, measured by the Sheffield TKV Tool,
was close to the manually measured TKV (2408 ± 1806 ml).
The mean volume error (Table 3, Fig. 4c) between the
Sheffield TKV Tool and the manual reference for the external
dataset was 3.45 ± 3.96%. This overall positive mean (bias)
difference indicates the manual volume was greater than the
value obtained by the tool. We attributed this mainly to the
method of manual segmentation (AnalyzeDirect), which leaves
a slight border around the kidney. The higher resolution of the
internal dataset (pixel spacing 0.68 mm) compared to the exter-
nal dataset (pixel spacing 1.5 mm) and the use of different
scanners could also have contributed to this difference.
Finally, the training dataset to determine values of parameters
used in level set function was obtained from the internal dataset
(61 patients) and was not optimised for the external dataset.
Nonetheless, standard deviation (precision) values were com-
parable to the initial results obtained during development of the
tool (Table 1). The higher mean volume error for right KV is
likely to be secondary to the low contrast between the right
kidney and liver, which was often very cystic. This difference
was more prominent in the external dataset (Table 3) where the
kidneys were clearly larger (twice the volume of the internal
dataset) representing patients with later-stage disease consistent
with their recorded age and renal function.
Time taken to measure TKV
The average time taken to measure TKV by manual segmen-
tation was 44 ± 18 min. In comparison, the Sheffield TKV
Tool took 5.6 ± 1.5 min on the Sheffield cohort and 5 ±
3 min on the external validation cohort. The mean time to
perform ellipsoid, mid-slice and MIROS methods was 4.5 ±
0.6, 3.2 ± 0.8 and 6.5 ± 2.2 min, respectively.
Table 4 shows the number of misclassified patients
assigned to Mayo imaging classes (1A–1E) based on TKV
calculated using various methods (manual, ellipsoid, mid-
slice, MIROS and Sheffield TKV Tool). Compared to the
manual method, the Sheffield TKV Tool misclassified 2 pa-
tients from class 1C to 1B and 1 patient from class1A to 1B.
However, these two patients were misassigned from class 1C
to 1B and class 1A to 1B by all four methods: in this case, the
value for manual HtTKV was borderline between class 1B
and 1C (age 51 years, HtTKV 678 ml) or between class 1B
and 1A (age 36 years, HtTKV 256 ml) (please refer [6] Supp
Table 2 Intra- and inter-operator variability to assess reproducibility and precision of the Sheffield TKV Tool
Comparison % volume difference
(mean ± SD)
Raw volume difference
(ml) (mean ± SD)
CoV (coefficient
of variation) (%)
Right KV Manual segmentation Intra-operator (Bmanual1 vs. Bmanual2) 1.1 ± 2.6 5.4 ± 10.6 1.9
Inter-operator (Amanual vs. Bmanual1) 0.9 ± 3.4 7.5 ± 12.5 2.4
Sheffield TKV Tool Intra-operator (BSheffieldTKVTool1
vs. BSheffieldTKVTool2)
− 0.1 ± 1.3 1.3 ± 4.2 1.0
Inter-operator (ASheffieldTKVTool
vs. BSheffieldTKVTool1)
1.5 ± 4.6 3.5 ± 22.1 3.4
Left KV Manual segmentation Intra-operator (Bmanual1 vs. Bmanual2) 0.1 ± 2.2 1.0 ± 11.0 1.5
Inter-operator (Amanual vs. Bmanual1) 0.2 ± 3.6 0.4 ± 14.7 2.5
Sheffield TKV Tool Intra-operator (BSheffieldTKVTool1
vs. BSheffieldTKVTool2)
−0.3 ± 1.3 − 1.0 ± 6.9 0.9
Inter-operator (ASheffieldTKVTool
vs. BSheffieldTKVTool1)
1.0 ± 3.1 7.4 ± 17.6 2.3
Results obtained from a subset of 20 patients (40 kidneys). KV kidney volume, SD standard deviation







Right KV Manual (reference) 1149 ± 871 – –
Sheffield TKV Tool 1109 ± 862 3.91 ± 5.24 40.35 ± 60.38
Left KV Manual (reference) 1259 ± 966 – –
Sheffield TKV Tool 1235 ± 981 3.14 ± 4.95 23.46 ± 99.42
TKV Manual (reference) 2408 ± 1806 – –
Sheffield TKV Tool 2344 ± 1806 3.45 ± 3.96 63.81 ± 142.81
The reference TKV was provided by manual TKV measurements at University of Groningen using AnalyzeDirect 11.0 software (Spithoven Est TKV
AJKD 2015). SD standard deviation, KV kidney volume, TKV total kidney volume
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Table S2). In the third patient, the Sheffield TKV Tool signif-
icantly undersegmented the kidney region due to the presence
of large cysts, a current limitation (see later). Overall, class
assignment based on the Sheffield TKV Tool was comparable
to the mid-Slice and MIROS methods and performed better
than the ellipsoid method which misclassified 8 patients in
total, 6 between classes 1B and 1C (Table 4).
Discussion
We report a new semi-automated method (Sheffield TKV
Tool) to measure TKV from MRI in ADPKD. The tool can
run independently as a self-contained package and requires
minimal user interaction to define a kidney outline from a
coronal T2-weighted sl ice. Compared to manual
segmentation, it performed with high accuracy in an unselect-
ed group of patients with a wider spectrum of disease than
previously reported, as represented by kidneys with highly
variable morphology, cyst burden, intensity distribution and
extensive range of TKV (range 258–7431 ml). Importantly, it
performed with high precision with no bias in measurements
of the right or left kidneys, high agreement (mean DSC 0.90 ±
0.05, TKV difference − 0.3 ± 3.8%) and reproducibility (1.1 ±
2.9%) compared to the manual method. Validation in a repre-
sentative external group of 65 patients with ADPKD con-
firmed good performance (mean volume error 3.45 ± 3.96%)
with the positive bias caused by the method of manual seg-
mentation which includes a slight border around the kidney.
A direct comparison between the Sheffield TKV Tool and
two estimation methods (ellipsoid and mid-slice) in the same
patients showed that it was more accurate and precise than
Fig. 4 Bland–Altman analysis of
Sheffield TKV Tool to measure
TKV compared to the reference
manual method for external
(Groningen) dataset. a Right
kidney volume. b Left kidney
volume. c Total kidney volume.
Bland–Altman plots (bold line,
mean; dashed lines, 95%
confidence intervals) comparing
the percentage (%) volume
difference of tool to the reference
manual method to measure TKV
in 65 patients
Table 4 Number of class 1 (A–E)
ADPKD (out of 51) patients [6]
misclassified based on TKV
measured using various TKV
measurement tools. Assignment
by manual TKV measurements
was used as reference
TKV measurements methods Class 1 misclassification
A to B B to A B to C C to B C to D Total
Ellipsoid method 1 0 3 3 1 8
Mid-slice method 1 0 0 1 1 3
MIROS tool 1 1 0 1 0 3
Sheffield TKV Tool 1 0 0 2 0 3
Eur Radiol
either. Unlike the estimation methods, it also clearly outlined
the kidney boundaries: these could be used as a precursor for
the segmentation of renal cysts [27]. The Sheffield TKV Tool
also performed as well as the MIROS [18] method in terms of
precision and accuracy (Table 1). MIROS requires more man-
ual interaction for larger kidneys and will therefore likely re-
quire more time in higher risk patients (Mayo class 1 C–E)
since the user must draw a polygon in between slices to initiate
kidney segmentation, unlike the Sheffield TKV Tool where
manual interaction is independent of kidney size.
The Sheffield TKV Tool also performed better (TKV differ-
ence − 0.3 ± 3.8%) when compared to other published semi-
automated methods [12, 28] (Table S1). Turco et al [28] report-
ed a greater volume difference (− 1.3 ± 3.9%) in 30 patients
despite a smaller TKVrange (693–2029 ml). Kim et al reported
a larger volume error of 4.2 ± 16.8% in 30 patients for training
and 30 for validation and a smaller volume range of 177–
2634ml with their automatic method [12]. Although nomanual
interaction is required when measuring TKV with their tech-
nique, large volume errors (≥ 40% in 4 patients) resulted in the
subsequent need for manual verification after segmentation.
In terms of efficiency, the reduced time required for the
Sheffield TKV Tool would enable 8–10 TKV measurements
to be performed in the time taken for a single manual TKV
measurement. It performed particularly well on larger kidneys
and in a wider range of kidney volumes (258–7431 ml) than
previously reported (largest 2837 ml) [18, 28].
Liver cysts can cause considerable challenges when mea-
suring TKV because of the close proximity of the liver with
the right kidney and less often the left kidney (with much
enlarged polycystic livers), since the distribution of cysts be-
tween the two neighbouring organs can be indistinguishable.
However, in most cases, the Sheffield TKV Tool was able to
distinguish between liver and kidney cysts even when the
visual boundaries appeared vague. There was no influence
of imaging classification on the performance of the Sheffield
TKV Tool: it performed equally well in class 1 and class 2
patients. This is a considerable advantage since no patients
requiring TKV measurements need to be excluded.
The current limitations of the Sheffield TKV Tool are a slight
undersegmentation and measurement of TKV in kidneys associ-
ated with exophytic cysts or oversegmentation associated with
large blood vessels especially when the kidney regions are small
(Fig. S1j). It has been developed for use on T2-weighted MR
sequences and has not been validated on T1-weighted images.
However, a recent comparison of T1- or T2-weighted images for
measuring TKV has reported that T2-weighted images were fre-
quently of better quality to enable TKV measurements and were
associated with improved reproducibility with lower intra- and
inter-reader variability [29].
It has not yet been tested for serial measurements of TKV
measurements to monitor natural history or response to treat-
ment. A future goal is therefore to apply image registration
techniques for this purpose [30]. Finally, the misclassification
of 2 patients to a lower risk class (1C to 1B) based on TKV
suggests that in cases with borderline TKV values between
classes or with atypical outlines leading to undersegmentation,
manual reanalysis may be required [6].
In summary, the accuracy, reproducibility and rapidity of
the Sheffield TKV Tool highlight its potential for wider adop-
tion to measure TKV as a prognostic marker routinely in pa-
tients with ADPKD.
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